Effectiveness of Butorphanol Intra Articular Injection in Signs and Symptoms of Internal Disorders of the Temporomandibular Joint Among Yemeni Patients in Sana'a City.
Main Article Content
Abstract
Background and aim: TMJ arthralgia is a painful ailment that is thought to be related to local inflammation in the jaw joint. The purpose of the current study was to evaluate the effectiveness of a single intra-articular (IA) injection of butorphanol into the TMJ for lowering pain and improving mouth opening. The concept was that butorphanol would significantly lessen TMJ pain and improve mouth opening.
Methods: Eleven patients were treated in this serie, which was followed up on for three months. Participants in the study had to be at least 18 years old and have a unilateral TMJ arthralgia diagnosis. Butorphanol IA injections weighing 1 mL were given to all individuals. The main result was an analysis of the per protocol population's change in recorded pain intensity on a visual analogue scale (VAS) at maximum jaw opening.
Results: Mouth opening improved after treatment as values increased: 1 week after treatment mean ± SD = 3.072 ± 0.373, after 1 month of treatment the values of mouth opening increased significantly, the highest values occurred after 3 months of treatment where the mouth-opening values were twice the pre-treatment period. Pre-treatment central trend measures of pain score were: the mean ± SD =7.364 ± 1.12, the pain score decreased after treatment, one week after treatment the mean ± SD =3.636 ± 1.748, one month after treatment values decreased significantly, the lowest pain scores occurred after 3 months of the treatment in which 25% of patients recorded 0 pain and 75% of patients recorded 1 or less pain score.
Conclusion: Following a single-dose IA injection, butorphanol was beneficial for lowering pain and improving mouth opening in individuals with TMJ arthralgia.
Downloads
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.